ED
KNSA icon

Exane Derivatives’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Exane Derivatives’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$92K Hold
9,496
– – 0.05% 271
2022
Q1 		$94.4K Sell
9,496
-811
-8% -$8.59K 0.03% 479
2021
Q4 		$121K Sell
10,307
-466
-4% -$5.73K 0.03% 423
2021
Q3 		$123K Buy
10,773
+1,268
+13% +$16.5K 0.03% 495
2021
Q2 		$131K Buy
9,505
+2,941
+45% +$44.7K 0.03% 511
2021
Q1 		$121K Sell
6,564
-1,299
-17% -$26.6K 0.03% 391
2020
Q4 		$139K Buy
7,863
+2,580
+49% +$45.3K 0.04% 349
2020
Q3 		$80.9K Buy
5,283
+1,033
+24% +$19.4K 0.02% 335
2020
Q2 		$108K Sell
4,250
-1,640
-28% -$34.3K 0.03% 281
2020
Q1 		$91.2K Buy
+5,890
New +$92.1K 0.03% 291

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Exane Derivatives's KNSA Position: Q2 2022 in Review

Exane Derivatives held its Kiniksa Pharmaceuticals (KNSA) position steady in Q2 2022 at 9,496 shares worth $92K. The position accounts for 0.05% of the portfolio, ranked #271.

Exane Derivatives first reported a position in KNSA in Q1 2020 and has held it in 10 quarters since. The position peaked at $139K in Q4 2020. 92 funds tracked by Wall St. Rank hold KNSA as of Q2 2022.

  • Exane Derivatives held 9,496 shares of Kiniksa Pharmaceuticals worth $92K as of Q2 2022.
  • Exane Derivatives left its Kiniksa Pharmaceuticals share count unchanged in Q2 2022.
  • Kiniksa Pharmaceuticals made up 0.05% of Exane Derivatives's portfolio in Q2 2022, its #271 holding.
  • Exane Derivatives first reported a position in Kiniksa Pharmaceuticals in Q1 2020 and has held it in 10 quarters since.
  • Exane Derivatives's Kiniksa Pharmaceuticals position peaked at $139K in Q4 2020.
  • 92 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.